



Selective melanocortin receptor ligands

Potential dual-ligand approach to weight management

Technology ID

20160305

Category

Life Sciences/Human Health
Life Sciences/Pharmaceuticals
Life Sciences/Therapeutics
Agriculture &
Veterinary/Veterinary Medicine




Fig. 1. C18 increases feeding and weight gain (A & B) while suppression with C11 decreases feeding and body weight (C & D). Sweeney *et al.*, 2021.

IP Status: Issued US Patent; Issued Patent No. 10,899,793

Applications

Learn more



- Anti-obesity, weight-loss therapy
- Anti-anxiety
- Anti-anorexia-cachexia therapy

Key Benefits & Differentiators

- **MC3R ligands:** address obesity; reduces appetite and anxiety
- **MC3R ligands:** effect on feeding, independent of behavioral stress, does not show sexual dimorphism

Technology Summary

Obesity is an epidemic in the United States where 42% of adults are obese leading to about 300,000 deaths per year. The socio-economic burden of obesity is nearly \$1.4 trillion. Cachexia associated with chronic illnesses such as cancer, heart failure (HF), kidney disease (CKD), and chronic obstructive pulmonary disease (COPD) remains unaddressed. Annually, over 160,000 people are admitted into hospital due to cachexia. Cancer patients often suffer from cachexia which negatively impacts their quality of life. Annually, mortality rates of patients with cachexia range from 10 to 15 % in COPD, 20–30 % in chronic HF and CKD to 80 % in cancer. These eating disorders present a significant unmet clinical need for efficacious treatments.

Seeking therapeutic solutions for these disorders, researchers at the University of Minnesota developed a tetrapeptide scaffold [Ac-Xaa1-Arg-(pI)DPhe-Xaa4-NH₂] used to design compounds that bind specifically to MC3R. MC3R plays a critical role in controlling appetite and mediating weight and is an attractive target for new therapies. Two MCR3 modulators, C18 agonist and C11 antagonist, were examined in mice for their ability to regulate feeding behavior. C18 or C11 were administered intracerebroventricularly and showed that C18 stimulated food intake and reduced anxiety-related behavior. Conversely, the C11 suppressed food intake and reduced weight gain (Fig. 1). Taken together, the MC3R bidirectionally regulated feeding C18 or C11 are potential therapeutic molecules for eating disorders.

Phase of Development

TRL: 4-6

In vivo mouse evaluation

Desired Partnerships

This technology is now available for:

- License
- Sponsored research
- Co-development

Please contact our office to share your business' needs and learn more.

Researchers

- [Carrie Haskell-Luevano, PhD](#) Professor, Department of Medicinal Chemistry

Licensing Terms

MN-IP Try and Buy

Try

- Trial period is up to 24 months
- Trial fee is \$0 for 12 months and \$6,000 for second 12 months
- No US patent fees during Try period

Buy

- \$25,000 licensee fee
- First \$1M cumulative sales are royalty-free
- Sublicense freely
- Royalty rate: 3% of Net Sales (2% for MN-based company)
- Patent(s) expenses paid by licensee
- Transfer fee for transferring license to a third party - \$25,000

References

1. Doering, S.R., Freeman, K.T., Schnell, S.M., Haslach, E.M., Dirain, M., Debevec, G., Geer, P., Santos, R.G., Giulianotti, M.A., Pinilla, C. and Appel, J.R ,
<https://doi.org/10.1021/acs.jmedchem.7b00301>, Journal of medicinal chemistry
2. Sweeney, P., Bedenbaugh, M.N., Maldonado, J., Pan, P., Fowler, K., Williams, S.Y., Gimenez, L.E., Ghamari-Langroudi, M., Downing, G., Gui, Y. and Hadley, C.K ,
<https://www.science.org/doi/10.1126/scitranslmed.abd6434>, Science Translational Medicine